Stock Fundamentals

Company Information

Company Name
Autolus Therapeutics Ltd
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US05280R1005
CIK: 0001730463
CUSIP: 05280R100
Currency: USD
Full Time Employees: 752
Phone: 44 20 3829 6230
Fiscal Year End: December
IPO Date: Jun 22, 2018
Description:

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Address:

The Mediaworks, London, United Kingdom, W12 7FP

Directors & Officers

Name Title Year Born
Dr. Christian Martin Itin Ph.D. CEO & Director 1964
Dr. Martin Pule M.D., MBBS Founder, Senior VP & Chief Scientific Officer 1972
Mr. Robert F. Dolski Senior VP & CFO 1971
Mr. Christopher Vann Senior VP & COO 1965
Mr. Patrick McIlvenny Senior VP of Finance, Chief Accounting Officer & Principal Accounting Officer 1980
Ms. Miranda Neville Senior VP & Chief Technology Officer 1975
Mr. Alex Driggs Senior VP of Legal Affairs & General Counsel and Secretary 1976
Mr. Alexander Swan Senior VP & Chief Human Resources Officer 1965
Dr. Christopher Williams Ph.D. Senior VP & Chief Business Development Officer 1980
Dr. Matthias Will M.D. Senior VP & Chief Development Officer 1973

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Mak Capital One LLC 33.62M Mar 31, 2026 12.63% $6.84 12.05%
Blackstone Inc 20.49M Mar 31, 2026 7.70% $0.11 0.00%
Syncona Portfolio Ltd. 16.64M Mar 31, 2026 6.25% $89.34 0.00%
Armistice Capital, LLC 15.80M Mar 31, 2026 5.94% $0.39 -9.71%
Polygon Management Ltd 9.50M Mar 31, 2026 3.57% $2.55 0.00%
Schroder Investment Management Group 9.49M Mar 31, 2026 3.57% $0.01 0.00%
Frazier Life Sciences Management, L.P. 4.45M Mar 31, 2026 1.67% $0.16 -3.79%
BNP Paribas Investment Partners SA 3.36M Mar 31, 2026 1.26% $0.01 0.00%
LAURION CAPITAL MANAGEMENT LP 3.32M Mar 31, 2026 1.25% $0.20 0.00%
Renaissance Technologies Corp 2.30M Mar 31, 2026 0.86% $0.01 -25.95%
Bank of America Corp 1.84M Mar 31, 2026 0.69% $0.00 -5.92%
BlackRock Inc 1.48M Mar 31, 2026 0.56% $0.00 -59.83%
UBS Group AG 1.31M Mar 31, 2026 0.49% $0.00 48.87%
Cetera Investment Advisers 1.13M Mar 31, 2026 0.42% $0.00 2.67%
Balyasny Asset Management LLC 971.69K Mar 31, 2026 0.37% $0.00 0.00%
Morgan Stanley - Brokerage Accounts 941.82K Mar 31, 2026 0.35% $0.00 -32.59%
JPMorgan Chase & Co 935.40K Mar 31, 2026 0.35% $0.00 -4.48%
Alphabet Inc 698.26K Mar 31, 2026 0.26% $0.02 0.00%
Marex Group PLC 542.86K Mar 31, 2026 0.20% $0.00 0.00%
Citadel Advisors Llc 459.40K Mar 31, 2026 0.17% $0.00 -60.39%

Shares Statistics

Shares Outstanding: 266.14M
Shares Float: 33.90M
% Insiders: 1,808.20%
% Institutions: 7,620.80%
Short % Float: 7.41%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 International Biotechnology Ord 7.82M 2.94% ▲ 0.00% Feb 28, 2026
2 AXA Framlington Health Fund - R Income 3.36M 1.26% ▲ 0.00% Apr 30, 2026
3 iShares Biotechnology ETF 1.34M 0.50% ▲ 1.95% May 29, 2026
4 JPM Thmtcs Gentc Thrps C2 dist USD 914.89K 0.34% ▲ 0.59% Apr 30, 2026
5 BGF World Healthscience A2 706.23K 0.27% ▲ 0.00% Feb 28, 2026
6 BlackRock Health Sciences Term Trust 361.23K 0.14% ▼ 22.15% Dec 31, 2025
7 MGTS Sentinel Navigator B Acc 287.15K 0.11% ▲ 39.94% Apr 30, 2026
8 Regnan Global Equity Imp Solu F GBP Acc 231.11K 0.09% ▼ 39.18% Oct 31, 2025
9 Ashburton Global Equity Growth D USD 214.64K 0.08% ▲ 11.42% May 31, 2026
10 ERSTE STOCK BIOTEC EUR R01 A 195.00K 0.07% ▲ 0.00% Apr 30, 2026

Valuation Metrics

Enterprise Value: $267.04M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $415.18M
EBITDA: $-68.94M
Book Value: $5.91
Earnings/Share: $-1.09
Profit Margin: 0.00%
Operating Margin: -6,570.75%
ROA (TTM): -22.28%
ROE (TTM): -29.62%
Revenue (TTM): $1.08M
Revenue/Share (TTM): $0.03
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 83,655.20%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 5.94x 0.08x 0.70x -7.66x -0.06x
2024-12-31 10.88x 0.01x 0.45x -25.98x -0.01x
2023-12-31 6.15x 0.05x 0.70x -3.99x -0.03x
2022-12-31 9.18x 0.02x 0.39x -16.05x -0.04x
2021-12-31 12.15x 0.01x 0.23x -127.04x -0.03x
2020-12-31 5.77x 0.02x 0.29x -160.56x -0.02x
2019-12-31 9.98x 0.01x 0.16x -215.66x -0.02x
2018-12-31 15.91x 0.00x 0.06x -4,541.96x 0.00x
2018-09-30 15.91x 0.00x 0.06x -4,541.96x 0.00x
2017-12-31 28.31x 0.00x 0.04x -616.26x 0.00x
2016-12-31 11.31x 0.00x 0.10x -293.39x 0.00x
2015-12-31 5.90x 0.00x 0.09x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about AUTL.US!